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Abstract
Background: LATS2, which encodes a novel serine/threonine kinase, is known to be important in centrosome
duplication and in the maintenance of genomic stability. Recently, a potential role for LATS2 in cancer has been
reported. In breast cancer and acute lymphoblastic leukemia (ALL), LATS2 mRNA is downregulated and has been
suggested to be a tumor suppressor. However, the role of LATS2 in nasopharyngeal carcinoma has not been
investigated. In this study, we aimed to investigate the expression pattern of LATS2 and its clinicopathological
involvement in nasopharyngeal carcinoma to understand its effect on cell survival.
Methods: Using quantitative real time PCR and immunoblotting, the expression of LATS2 was detected in
nasopharyngeal carcinoma cell lines and in the immortalized nasopharyngeal epithelial cell line NP69. Using
immunohistochemistry, we analyzed LATS2 protein expression in 220 nasopharyngeal carcinoma cases. The
association of LATS2 protein expression with the clinicopathological characteristics and the prognosis of
nasopharyngeal carcinoma were subsequently assessed. Using methylation specific PCR, we detected the
methylation status of the LATS2 promoter. RNA interference was performed by transfecting siRNA to specifically
knock down LATS2 expression in 5-8F and CNE2.
Results: LATS2 protein was detected in 178 of 220 (80.91%) cases of nasopharyngeal carcinoma. LATS2
overexpression was a significant, independent prognosis predictor (P = 0.037) in nasopharyngeal carcinoma
patients. Methylation specific PCR revealed that 36.7% (11/30) of nasopharyngeal carcinoma tissues and all of the
chronic nasopharyngeal inflammation samples were methylated. Functional studies showed that the suppression of
LATS2 expression in nasopharyngeal carcinoma (5-8F and CNE2) cell lines by using specific small interfering (siRNA)
resulted in the inhibition of growth, induction of apoptosis and S-phase cell cycle increase. Overexpression of
LATS2 in NP69 stimulated cell proliferation.
Conclusions: Our results indicate that LATS2 might play a role in the tumorigenesis of nasopharyngeal carcinoma
by promoting the growth of nasopharyngeal carcinoma cells. Transfection with specific siRNA might be feasible for
the inhibition of growth, induction of apoptosis and S phase increase in nasopharyngeal carcinoma.
Background
Nasopharyngeal carcinoma (NPC) is endemic to certain
areas of Southern China, South-Asia and North Africa.
In Southern China in the Guandong and Guangxi pro-
vinces, the incidence rate of NPC is up to 25-40 per
100,000 person-years [1,2]. A dominant clinicopathologi-
cal characteristic of NPC is the involvement of cervical
lymph nodes and distant metastasis, compared with
other head and neck carcinomas. Although the current
treatment regimen for NPC is fractionated radiotherapy,
adjunctive chemotherapy has shown promise by improv-
ing tumor control and survival in advanced nasopharyn-
geal carcinoma [3-5]. NPC is associated with a high rate
of treatment failure because of local recurrence and
distant metastasis [6-8]. Published reports indicate that
the etiologic factors associated with NPC are genetic
susceptibility [9], EBV infection [10], and other environ-
mental factors [11,12]. However, the precise genetic
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alterations responsible for NPC development, progres-
sion and metastasis are unknown. Therefore, it is of
great clinical value to find factors for early diagnosis
and prognosis prediction, as well as novel therapeutic
strategies, and it is critical to further understand the
molecular mechanism of NPC.
LATS2 (Large Tumor Suppressor homolog 2), also
known as Kpm, is one of the two human homologues of
Drosophila wts, which is a component of the Hippo path-
way. This pathway is now known to control organ size by
modulating cell growth, proliferation, and apoptosis
[13,14]. Recent work suggests that LATS2 regulates both
growth and death of cardiac myocytes, and that it is a
negative regulator of myocyte size in the heart [15].
LATS2 inhibits cell proliferation by inducing G2/M arrest
through the inhibition of cdc2 kinase activity [16], or by
blocking G1/S transition through the down-regulation of
cyclin E/CDK2 kinase activity [16,17]. Ectopic expression
of LATS2 in human lung cancer cells induces apoptosis
via down-regulation of apoptotic inhibitors such as Bcl-2
and Bcl-xL [18]. LATS2 binds to Mdm2 and inhibits its
E3 ubiquitin ligase activity, resulting in the stabilization of
p53 in nocodazole treated cells, while p53 rapidly and
selectively up-regulates LATS2 expression in G2/M cells.
This process is therefore a positive feedback loop between
p53 and LATS2 [19]. LATS2 is also required for embryo-
nic development, proliferation control and genomic integ-
rity [20,21]. LATS2 -/- MEFs display defects in contact
inhibition of growth, cytokinesis failure, centrosome
amplification, multipolar mitotic spindles and genomic
instability. However, disruption of LATS2 results
in embryonic lethality. In LATS2-/- embryos, the develop-
ment of the nervous system was severely impaired, and
deficiency in LATS2 results in growth arrest and
apoptosis.
LATS2 has not been widely studied in the field of can-
cer. The aim of the present study is thus to investigate the
expression pattern of LATS2 and its clinicopathological
implication for NPC, and to further understand its effect
on cell survival. We showed that overexpression and de-
methylation of LATS2 occurred very frequently in NPC
tissues, and overexpression of LATS2 predicted poor prog-
nosis of NPC patients. Furthermore, suppression of
LATS2 expression resulted in growth inhibition, apoptosis
and S-phase increase. Overexpression of LATS2 stimu-
lated cell growth. These results suggest that LATS2 might
play a role in the tumorigenesis of NPC and might be a
potential therapeutic target in NPC treatment.
Methods
Patients and clinical tissue samples
For this retrospective study, archival formalin-fixed, par-
affin-embedded specimens from 220 primary NPC
patients during 1992 ~ 2002 in Sun Yat-Sen University
Cancer Center (Guangzhou, China) were collected.
All the NPC samples in our study were obtained before
treatment with standard curative radiotherapy with or
without chemotherapy. Patients included 166 males and
54 females with ages ranging from 14 to 86 years (med-
ian age 46 years). The disease stages of all the patients
were classified according to the 1992 NPC staging
system of China as mentioned before [22]; 6 patients
were in stage I, 48 patients in stage II, 103 patients in
stage III and 63 patients in stage IV. Among 220
patients, 58 patients were diagnosed as differentiated
non-keratinising carcinoma (WHO type II) and 162
patients were diagnosed as undifferentiated carcinoma
(WHO type III). All patients were treated with standard
curative radiotherapy with or without chemotherapy.
Information on date of death and cancer as the cause of
death was obtained from the Sun Yat-Sen University
Cancer Center Registry. Patients who died from diseases
other than NPC or from unexpected events were
excluded from the study. The median follow-up period
was 44 months (range, 2-120 months). A total of 66
(30.00%) patients died during follow-up and 29 (13.18%)
patients experienced metastasis. The study was approved
by the Research Ethics Committee of Sun Yat-Sen
University Cancer Center (Reference number: YP-
2009169)
Tissue microarray construction
Paraffin-embedded specimens from the previously con-
structed tissue microarray (TMA), and the procedures
for the TMA construction were described previously
[23,24]
Immunohistochemistry
Immunohistochemistry was performed to examine
LATS2 and p-YAP (Phospho-YAP [Ser127]) expression
in nasopharyngeal carcinoma tissue specimens. A pri-
mary antibody against LATS2 (1:400 dilution, sc-23065,
Santa Cruz, USA) and p-YAP (1:200, #4911, Cell Signal-
ing Technology) were used in this study. The staining
protocol used was as previously described. The immu-
nohistochemistry results were evaluated and scored
independently by two pathologists without knowledge of
the clinicopathological outcomes of the patients.
A semiquantitative estimation was made using a compo-
site score obtained by adding the values of the staining
intensity and the relative abundance of the positive cells.
The intensity was graded as 0 (negative), 1 (weakly posi-
tive), 2 (moderately positive) and 3 (strongly positive).
The abundance of the positive cells was graded from 0
to 4 (0, < 5% positive cells; 1, 5-25%; 2, 26-50%; 3,
51-75%; 4, 76-100%). A composite score greater than or
equal to the median value was considered high expres-
sion, and composite scores below the mean value were
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considered low expression. To ensure the specificity of
LATS2 antibody, non-immunized goat IgG antibody was
used as a negative control.
Immunohistochemistry of cultured cells was performed
as follow. Cultured cells were harvested and washed thrice
with PBS. Then resuspended with PBS and centrifuged on
the slides by cytospin machine Rotofix 32 (Hettich,
Germany). The cells on the slides were fixed with 4% par-
aformaldehyde for 30 min, permeabilization steps
followed, cover cells with 0.25% Triton X-100 for 15 min.
Immunohistochemistry was performed to examine LATS2
expression in 5-8F cells or transfected cells.
Methylation specific PCR
Genomic DNA was isolated from microdissected NPC
samples and NPC cell lines, and then modified by sodium
bisulfite [25]. The methylation status of the promoter
regions of LATS2 was previously reported [26]. Modified
DNA was prepared for PCR with methylation-specific
primers (5’-ATT TCG GTT TAT TGT AAT TTT C-3’
and 5’-AAC CAA CAT AAT AAA ACC CCG-3’) and
unmethylation-specific primers (5’-TTT GTT TTT TGG
GTT TAA GT-3’ and 5’-CCA ACA TAA TAA AAC
CCC A-3’) [26]. PCR was carried out in 25 μL containing
2 μL modified DNA, 2× GC buffer 12.5 μL (Takara,
Japan), 4×10 mmol/L dNTP 1 μL, 10 mmol/L of each pri-
mer 1 μL, and 5 U/μL Takara LA Taq DNA polymerase
0.25 μL (Takara, Japan). Further amplification conditions
were as follows: after initial denaturation at 94°C for 3
minutes, 40 cycles at 94°C for 30 seconds, 50°C for 30
seconds, and 72°C for 30 seconds, followed by a 6-minute
extension at 72°C. PCR products were separated on 2.5%
agarose gels and visualized under UV illumination with
ethidium bromide staining.
Cell lines and cell culture
The three NPC cell lines CNE1, CNE2, and 5-8F were
cultured in RPMI 1640 (Gibco, USA) with 10% fetal
bovine serum (Gibco, USA). The human NPC cell line
C666-1 was cultured in RPMI 1640 medium (GIBCO,
USA) containing 15% FCS. The immortalized nasophar-
yngeal epithelial cell line NP69 was cultured in keratino-
cyte serum-free medium (Invitrogen) supplemented with
5% FCS, 25 μg/ml bovine pituitary extract, and 0.2 ng/
ml recombinant epidermal growth factor, as suggested
by the manufacturer. All the cell lines were grown in a
humidified incubator at 37°C with 5% CO2.
Real time PCR assays
Total RNA was extracted from the NPC cell lines CNE1,
CNE2, 5-8F, C666-1 and an immortalized nasopharyngeal
epithelial cell line, NP69, as well as three NPC biopsies
and the paired normal tissues by using TRIzol reagent
(Invitrogen). After reverse transcription of the total RNA,
the first-strand cDNA was then used as template for
detection of LATS2 expression by using quantitative real
time PCR (QT-PCR) with the SYBR Green I chemistry
(ABI Inc., USA). GAPDH was used as control. The pri-
mers of LATS2 were (Forward: 5’-TGG CAC CTA CTC
CCA CAG-3’ and Reverse: 5’-CCA AGG GCT TTC TTC
ATC T-3’), GAPDH (Forward: 5’-CCA CCC ATG GCA
AAT TCC ATG GCA-3’ and Reverse: 5’-TCT AGA CGG
CAG GTC AGG TCC ACC-3’). Thermal cycle conditions
were: 1 cycle of pre-incubation at 95°C for 5 minutes
(segment 1); 40 cycles of amplification at 95°C for 30 sec-
onds, 58°C (LATS2) or 57°C (GAPDH) 45 seconds and
72°C for 45 seconds (segment 2); and melting temperature
curve analysis at 95°C for 30 seconds, 60°C for 30 seconds
and 95°C for 30 seconds (segment 3). The relative expres-
sion level was determined as 2-ΔΔCt. Data are presented as
the expression level relative to the calibrator (NP69 cells),
with the standard error of the mean of triplicate measures
for each test sample.
Cell transfection
Three siRNAs (GenePharma, China) designed against
LATS2 (GenBank accession no. NM_014572) were
included in this study. One control siRNA (GenePharma,
China) exhibiting no significant sequence similarity to
human, mouse or rat gene sequence served as a negative
control. The sequences for LATS2 specific siRNAs and
control siRNA are: siRNA1 (GCC UCA ACG UGG ACC
UGU ATT), siRNA2 (GGA CAA AGG CGG AAA GGA
UTT), siRNA3 (GGA CCU UCA CUG CAU UAA ATT)
and control siRNA (UUC UCC GAA CGU GUC ACG
UTT).
The plasmids for pCMVmyc-LATS2, described else-
where [27], were a gift of Dr Hiroshi Nojima (Osaka
University). Full LATS2 cDNA was released from the
pCMVmyc-LATS2 plasmid by BamHI and XhoI clea-
vage and recloned into the pcDNA3 vector to produce
pcDNA3-LATS2.
Transfection of siRNA and plasmid was performed
with lipofectamine 2000 transfection reagent (Invitrogen,
USA) following the manufacturer’s protocol. Transfected
cells were grown at 37°C for 6 h, followed by incubation
with complete medium.
Cell growth assay
For cell growth assay, at 24 h after the treatment, the
cells of each group were reseeded in 24-well plates at a
density of 0.8 × 104 cells per well, then harvested at
24-h intervals up to 6 days. The number of living cells
was counted with trypan blue exclusion.
MTT assay
For cell proliferation assay, at 24 h after transfection, the
cells of each group were reseeded in 96-well plates at a
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density of 2 × 103 cells/well and incubated overnight in
100 μL of the culture medium. Cells without any treat-
ment were used as controls. A volume of 20 μL of
5 mg/mL MTT (Sigma, USA) labeling reagent was
added to the wells, and cells were incubated at 37°C for
4 h. The supernatant was removed, then 150 μL
dimethyl sulfoxide (DMSO, Sigma, USA) was added to
the wells. After the plate was incubated at 37°C for 15
min, the absorbance was measured with a microplate
reader (SpectraMax M5, Molecular Devices USA) at a
wavelength of 570 nm.
Apoptosis assay
Apoptotic cell death was assessed by Annexin-V FITC
and propidium iodide (PI) double staining to discrimi-
nate apoptotic cells from live cells. In brief, after the
treatment, cells of each group were stained according to
the instructions of the Annexin-V FITC Apoptosis Kit
(Invitrogen, USA), and analyzed by a flow cytometer
(EPICS ELITE, COULTER, USA). The data were pre-
sented as dot plots showing fluorescence intensity of
Annexin-V FITC and PI.
Cell cycle analysis
After the treatment, cells were trypsinized and concen-
trated by mild centrifugation. The cell pellet was resus-
pended, washed three times with cold PBS, and fixed
with cold 75% ethanol at 4°C overnight. Then, the cells
were washed once with PBS and digested with RNase at
37°C for 30 min. Nuclei of cells were stained with propi-
dium iodide at room temperature for 30 min. A total of
10,000 nuclei were examined in a flow cytometer and
DNA histograms were analyzed by Modifit software
(Verity Software House, USA).
Immunoblot analysis
Cells were harvested and lysed with RIPA buffer
(Upstate, USA). Equal amounts of denatured protein
sample were separated by SDS-PAGE and then trans-
ferred electrophoretically to PVDF membranes (Amer-
sham, UK) for immunoblot analysis. Antibodies used for
immunoblot analysis were against LATS2 (1:500 dilu-
tion, sc-23065, Santa Cruz, USA), an anti-GAPDH anti-
body (1:3,000 dilution, sc-32233, Santa Cruz, USA) was
used as loading control. All protein bands were detected
using an enhanced chemiluminescent (ECL) Western
blot Kit (Amersham, UK).
Statistical analysis
Data were analyzed using SPSS13.0 software. Associa-
tions between the expression of LATS2 and clinico-
pathological parameters were assessed using a Chi-
Square test. Survival curves were plotted by Kaplan-
Meier analysis and compared by the log-rank test. Cox
regression analysis was performed to assess the signifi-
cance of various variables for survival. Results for the
cell growth assay were expressed as mean ± S.D, and
T-test was used to determine the significance of differ-
ences in multiple comparisons. P < 0.05 was considered
statistically significant.
Results
Expression of LATS2 and its association with
clinicopathological parameters in NPC
To determine LATS2 expression in NPC, quantitative
real-time PCR was performed to evaluate the expression
levels of LATS2 transcripts in the NPC cell lines CNE1,
CNE2, 5-8F and C666-1, in an immortalized primary
nasopharyngeal epithelial cell line NP69, as well as in
three NPC biopsies and their paired normal tissues.
Compared to NP69 cells, overexpression of LATS2
mRNA was observed in the NPC cell lines CNE1,
CNE2, 5-8F and C666-1. The expression levels of
LATS2 mRNA were also significantly up-regulated in
three NPC tumor tissues, compared to the paired nor-
mal tissues (Fig. 1A). Western-blot analysis also revealed
overexpression of LATS2 protein in CNE1, CNE2, 5-8F
and C666-1 cells, compared to NP69 cells (Fig. 1B)
Expression of LATS2 protein was determined by
immunohistochemistry in 220 NPC tissues. LATS2
immunostaining revealed that overexpression of LATS2
was observed in the nuclear and cytoplasm of NPC
carcinoma cells (Fig. 1C) and 5-8F cell line (Additional
file 1). LATS2 was expressed weakly in normal naso-
pharyngeal epithelium (Fig. 1D). However, no immunos-
taining signal was detected in NPC tumor tissue and
5-8F cell line incubated with a non-immunized goat IgG
antibody (Additional file 1). LATS2 protein was detected
in 178 of 220 (80.91%) cases of NPC. No significant
association between LATS2 expression and age, gender,
clinical stage, histological type (WHO), recurrence or
distant metastasis of NPC was observed (Table 1).
Association between LATS2 expression and survival of
NPC patients
The 5-year overall survival rate of the cohort of 220
NPC patients was 66.18% (Fig. 2A). Kaplan-Meier survi-
val analysis revealed that NPC patients with high LATS2
expression had a significantly poor prognosis compared
to those with low LATS2 expression. The 5-year survival
rates in patients with low LATS2 expression (n = 109)
and high LATS2 expression (n = 111) were 73.96% and
57.23%, respectively; there was a significant difference
between the two groups (log-rank test, X2 = 7.660, P =
0.006, Fig. 2B). When the patients were stratified by
clinical stage, LATS2 expression was not related to the
patients survival in the early stage (stage I - II) cases,
(log-rank test, X2 = 2.728, P = 0.099, Fig. 2C). Within
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Figure 1 Expression of LATS2 in NPC cell lines and NPC tumor tissues. A, The expression levels of LATS2 transcripts in the NPC cell lines
CNE1, CNE2, 5-8F and C666-1, and in immortalized primary nasopharyngeal epithelial NP69 cells, as well as in three NPC biopsies and one
paired normal epithelium were evaluated by quantitative real-time PCR. The NPC cell lines CNE1, CNE2, 5-8F and C666-1, as well as NPC tumors
(NPC1, NPC2 and NPC3) show a higher LATS2 mRNA expression level than immortalized primary nasopharyngeal epithelial NP69 cells and
normal nasopharynx epithelium (NPNE1). B, The LATS2 protein expression level was detected by western blot in the NPC cell lines CNE1, CNE2,
5-8F, C666-1 cells and in NP69 cells. C, LATS2 (IHC, × 200) staining revealed that overexpression of LATS2 was observed in the nuclear and
cytoplasm of carcinoma cells. D, Weak staining of LATS2 was observed in adjacent normal nasopharyngeal epithelial cells. H&E staining of NPC
carcinoma cells (E) and adjacent normal nasopharyngeal epithelial cells (F).
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the late stage cases (stage III - IV), Kaplan-Meier survi-
val estimates revealed that patients with high LATS2
expression (n = 86) had inferior survival to those with
low LATS2 expression (n = 80, log-rank test, X2 =
4.589, P = 0.032, Fig. 2D). When the patients were stra-
tified by histological type (WHO), LATS2 expression
was not related to patient survival in the type II cases,
(log-rank test, X2 = 2.351, P = 0.125, Fig. 2E). Within
the type III cases, Kaplan-Meier survival estimates
revealed that patients with high LATS2 expression (n =
81) had inferior survival to those with low LATS2
expression (n = 81, log-rank test, X2 = 4.207, P = 0.040,
Fig. 2F).
Univariate Cox proportional hazard regression analysis
revealed that high LATS2 expression was a significant
predictive factor for poor prognosis of patients with
NPC (Hazard ratio (HR) = 1.978, 95% confidence inter-
val [CI]: 1.207-3.241, P = 0.007,). Other clinicopatholo-
gic parameters, including gender (HR = 0.380, 95% CI:
0.193-0.746, P = 0.005), metastasis (HR = 2.578, 95% CI:
1.424-4.665, P = 0.002) were also found to be prognostic
predictors of overall survival in NPC patients (Table 2).
Multivariate Cox proportional hazards regression analy-
sis indicated that LATS2 expression (HR = 1.714, 95%
CI: 1.033 - 2.843, P = 0.037,), gender (HR = 0.437, 95%
CI: 0.219 - 0.874, P = 0.019) and metastasis ((HR =
2.677, 95% CI: 1.424 - 5.031, P = 0.002) were predictors
for death (Table 2).
Methylation analysis of LATS2 in NPC tumors
Methylation status of LATS2 was analyzed in 30 NPC
tissues and 23 nasopharyngeal chronic inflammation
samples. Methylation-specific PCR showed that LATS2
promoter methylation was present in 36.7% (11/30)
NPC tumor tissues compared with 23 (100%) chronic
nasopharyngeal inflammation epithelium samples.
(Fig. 3). These results indicated that there was an
increased de-methylation frequency of LATS2 in NPC
tumor tissues (P < 0.01). In NPC cell lines, LATS2 pro-
moter methylation was detected in CNE1 and NP69.
LATS2 siRNA1 transfection effectively suppresses LATS2
expression
Three siRNAs (50 nM) designed against different
regions of LATS2, and a control siRNA (50 nM) were
transfected into the 5-8F cell line that showed overex-
pression of LATS2 based on western blotting results.
Cells transfected with LATS2 siRNA1 showed a 78%
Table 1 Correlation between LATS2 expression and clinicopathological parameters of NPC
Parameters Cases (n = 220) LATS2 expression P value
Low expression (n = 109) High expression (n = 111)
Age
< 46 104 56 48 0.227
≥46 116 53 63
Gender
Male 166 77 89 0.100
Female 54 32 22
T stage
T1+T2 90 49 41 0.227
T3+T4 130 60 70
N stage
N0 58 29 29 0.936
N1+N2+N3 162 80 82
clinical stage
I + II 54 29 25 0.482
III + IV 166 80 86
Histological type (WHO)
II 58 28 30 0.882
III 162 81 81
Recurrence
Yes 54 26 28 0.813
No 166 83 83
Metastasis
Yes 29 14 15 0.883
No 191 95 96
Median age is 46 years.
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Figure 2 Kaplan-Meier survival curves of NPC patients. A, The five-year overall survival rate of 220 NPC patients was 66.18%. B, The five-year
overall survival rates were 73.96% and 57.23%, in NPC patients whose tumors showed low levels of LATS2 expression (n = 109) and high levels
of LATS2 expression (n = 111), respectively; there was a significant difference in the overall survival rate between the two groups (P = 0.006). C,
No significant differences in five-year survival rates were found between low levels of LATS2 expression (n = 29) and high levels of LATS2
expression (n = 25) in NPC patients with early stage disease (stage I - II, P = 0.099). D, The five-year overall survival rates were 70.57% and 57.59%
in patients with late stage disease (stage III - IV) whose tumors showed low levels of LATS2 expression (n = 80) and high levels of LATS2
expression (n = 86), respectively; there was a significant difference in the overall survival rate between the two groups (P = 0.032). E, No
differences were found in overall survival between low levels of LATS2 expression (n = 28) and high levels of LATS2 expression (n = 30) in NPC
patients with differentiated non-keratinising carcinoma (WHO type II, P = 0.125). F, The five-year overall survival rates were 70.91% and 62.23% in
patients with undifferentiated carcinoma (WHO type III) whose tumors showed low levels of LATS2 expression (n = 81) and high levels of LATS2
expression (n = 81), respectively; there was a significant difference in the overall survival rate between the two groups (P = 0.040).
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decrease in LATS2 protein level compared to cells
transfected with control siRNA (Fig. 4A and 4B).
Transfection with LATS2 siRNA1 caused a dose
dependent decrease in LATS2 protein levels 72 h post-
transfection. Cells transfected with LATS2 siRNA1 (75
nM and 100 nM) showed a 94% decrease in LATS2 pro-
tein expression compared to cells transfected with con-
trol siRNA (Fig. 4C and 4D). Immunohistochemistry
analysis also revealed remarkably decreased expression
of LATS2 in nuclear of 5-8F cells transfected with
25 nM and 50 nM LATS2 siRNA1, and no expression
of LATS2 was observed in 5-8F cells treated with
75 nM LATS2 siRNA1 (Additional file 1). These results
suggested that immunostained signals are specific for
LATS2 protein, and siRNA mediated LATS2 knock-
down in the 5-8F cells resulted the reduction or disap-
pearance of these signals.
Silencing of LATS2 inhibits growth of 5-8F and CNE2 cells
To assess the effect of LATS2 siRNA1 on cell growth
and proliferation in NPC cell lines, 5-8F and CNE2 cells
were transiently transfected with LATS2 siRNA1
(75 nM) and control siRNA (75 nM). The total cell
number was quantified at 24 h intervals up to 6 days.
As shown in Fig. 5B, after transfection there was an
apparent decline in the cell number in the LATS2
siRNA1 treated group compared with the control siRNA
groups. Especially in 5-8F cells, there was significant
inhibition of growth (P < 0.05) beginning on the third
day after transfection.
Silencing of LATS2 induces apoptosis in 5-8F and CNE2
cells
Cells treated with LATS2 siRNA1 (75 nM) and control
siRNA (75 nM) for 72 h were evaluated for the presence
of apoptosis by flow cytometry. The percentage of apop-
totic cells was examined by Annexin-V and propidium
iodide (PI) double staining. The percentages of apoptotic
cells in 5-8F cells transfected with LATS2 siRNA1 and
control siRNA were 42.3% and 18.9%, respectively. In
the CNE2 cell line, the corresponding values were 34.6%
Table 2 Univariate and multivariate Cox regression
analysis of different prognostic varibles in patients with
NPC
Variable Subset Hazard ratio (95%
CI)
P
Univariate analysis (n = 220)
LATS2 expression High vs. Low 1.978(1.207-3.241) 0.007
Age < 46 vs. ≥46 1.563(0.957-2.552) 0.075
Gender Male vs. Female 0.380(0.193-0.746) 0.005
Clinical stage I, II vs. III, IV 1.717(0.932-3.165) 0.083
T-stage T1+T2 vs. T3+T4 1.477(0.889-2.457) 0.132





II vs. III 1.064(0.624-1.815) 0.820
Recurrence No vs. Yes 1.468(0.891-2.418) 0.132
Metastasis No vs. Yes 2.578(1.424-4.665) 0.002
Multivariate analysis (n = 220)
LATS2 expression High vs. Low 1.714(1.033-2.843) 0.037
Gender Male vs. Female 0.437(0.219-0.874) 0.019
Metastasis No vs. Yes 2.677(1.424-5.031) 0.002
Median age is 46 years
Figure 3 Methylation-specific PCR analysis of the LATS2 promoter. Mehtylation of the LATS2 promoter was detected in NPC tumor tissues
(A) and NPC cell lines (B). MC, a positive control for methylated alleles. UC, a positive control for unmethylated alleles. M, methylated. U,
unmethylated. The methylation-specific products (148 bp) and unmethylation-specific products (130 bp) were separated on 2.5% agarose gels.
Marker, 50 bp size marker. T, NPC tumor tissue. N, chronic inflammation of nasopharyngeal samples
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and 17.6%. The ratio of apoptotic cells increased in the
LATS2 siRNA1 transfected 5-8F and CNE2 cells as
compared to control siRNA transfected cells (Fig. 5C).
These results suggest that suppression of LATS2 can
lead to induction of apoptosis.
LATS2 silencing induces S-phase cell cycle increase in 5-
8F and CNE2 cells
The cell cycle distribution of transfected cells was exam-
ined by flow cytometry. In the 5-8F cell line, the percen-
tage of cells in G1, S and G2 phases in control siRNA
(75 nM) treated cells was 53.9%, 27.2% and 18.9%,
respectively, and in LATS2 siRNA1 (75 nM) treated
cells these percentages were 46.2%, 42.6% and 11.3%,
respectively (Fig. 5D). The number of LATS2 siRNA1
treated cells in S-phase was significantly increased,
reaching 42.6% 72 h after transfection. Similarly, the
proportion of S-phase cells was increased to 33.7% in
CNE2 cells transfected with LATS2 siRNA1 compared
with 25.7% in control siRNA-transfected cells 72 h after
culture. These results indicate that LATS2 silencing
results in S-phase cell cycle increase in 5-8F and CNE2
cells.
Overexpression of LATS2 stimulates cell proliferation
To investigate whether LATS2 overexpression is
involved in cell growth, the immortalized nasopharyn-
geal epithelial cell line NP69 was transfected with
pcDNA3-LATS2 and vector. As shown in Fig. 6C, the
growth of cells transfected with pcDNA3-LATS2 was
evidently increased compared to cells transfected with
pcDNA3. These time-effect curves indicated that LATS2
overexpression could stimulate the growth of NP69 cells
in vitro.
Discussion
The Drosophila warts/lats gene is considered to be a
tumor suppressor, and down regulation of LATS2
mRNA expression by promoter hypermethylation has
been reported to be associated with several malignan-
cies, including breast cancer [26], astrocytoma [28] and
acute lymphoblastic leukemia (ALL) [29]. Low expres-
sion of LATS2 mRNA has also been reported to be cor-
related with poor prognosis of patients with ALL [29].
In the present study, LATS2 protein was found to be
overexpressed in NPC tumor tissues and NPC cell lines.
These results suggest that LATS2 overexpression plays
Figure 4 LATS2 siRNA1 transfection effectively suppresses LATS2 expression. A, The 5-8F cell line was transfected with three siRNAs
(50 nM) to target LATS2 or with control siRNA (50 nM). Cell lysates were generated 72 h post-transfection, followed by immunoblot analysis to
determine LATS2 expression; GAPDH was used as the loading control. B, Densitometry analysis revealed that 5-8F cells transfected with LATS2
siRNA1 showed a 78% decrease in LATS2 protein expression compared to cells transfected with control siRNA. C, 5-8F cells were transfected
with different concentrations (25 nM, 50 nM, 75 nM and 100 nM) of LATS2 siRNA1 or with control siRNA. Cell lysates were generated at 72 h
post-transfection, followed by immunoblot analysis to determine LATS2 expression, GAPDH was used as the loading control. D, Densitometry
analysis revealed that 5-8F cells transfected with LATS2 siNRA1 (75 nM and 100 nM) showed a 94% decrease in LATS2 protein expression.
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Figure 5 Suppression of LATS2 expression inhibits growth, induces apoptosis and S-phase increase. A, 5-8F and CNE2 cell lines were
transfected with LATS2 siRNA1 (75 nM) or control siRNA (75 nM). Cell lysates were generated 72 h post-transfection, followed by immoblot
analysis to determine LATS2 expression. GAPDH was used as the loading control. B, Growth curve of 5-8F and CNE2 cells upon LATS2 silencing.
Results represent the means ± SD (n = 3).*p < 0.05. C, Flow cytometry analysis of apoptosis by using AnnexinV FITC and PI double staining 72 h
after transfection. The percentages of apoptotic 5-8F cells transfected with LATS2 siRNA1 and control siRNA were 42.3% and 18.9%, respectively.
In CNE2 cells, the percentages of apoptosis in cells transfected with LATS2 siRNA1 and control siRNA were 34.6% and 17.6%. D. Cell cycle
distribution was monitored by flow cytometry. The percentages of cells in S-phase in 5-8F cells transfected with LATS2 siRNA1 and control siRNA
were 42.6% and 27.2%, respectively. In CNE2 cells, the percentages of S-phase cells among those transfected with LATS2 siRNA1 and control
siRNA were 33.7% and 25.7%, respectively.
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an important role in the development and progression
of NPC. Our further retrospective tumor study showed
that LATS2 protein was detected in 80.91% (178 of 220
cases) of NPC specimens. It is worth noting that overex-
pression of LATS2 protein was found to be an indicator
of poor prognosis in NPC patients, and LATS2 expres-
sion, gender and metastasis were independent predictors
of NPC. These results suggest that, as an independent
risk factor, LATS2 could serve as a prognostic marker
for survival in NPC patients. Furthermore, we found
that in 36.7% of cases, the LATS2 promoter is methy-
lated in NPC tumor tissues, while the LATS2 promoter
was found to be methylated in all the chronic nasophar-
yngeal inflammation epithelium samples evaluated
(100%). However, this finding needs to be confirmed in
a larger series. The present results differ from previously
reported data on other malignant cancers, which showed
a decrease in LATS2 mRNA levels in tumor tissue
[26,28], implying that LATS2 may have different roles in
different types of cells and/or cancers.
LATS2 is a component of the Hippo pathway. In mam-
malian cells, central to the Hippo pathway is consisted of
four proteins including Mst1/2, WW45, LATS1/2 and
Mob1 [30]. Hippo signaling influences gene expression
by regulating transcriptional co-activator YAP (Yes-
kinase associated protein), which has a capacity to func-
tion either as an oncogene or a promoter of apoptosis
[31,32]. LATS1/LATS2 cooperate with the upstream
Mst2 kinase to phosphorylate YAP at Ser-127 and inacti-
vate its function as a stimulator of cell detachment [32].
Here we detected the expression of p-YAP in 122 NPC
tissues and showed that p-YAP expression was not
Figure 6 Overexpression of LATS2 stimulated cell growth. A, NP69 cells were transfected with pcDNA3-LATS2 or Vector. Cell lysates were
generated at 48 h post-transfection, followed by immunoblot analysis to determine LATS2 expression, GAPDH was used as the loading control.
B, Densitometry analysis revealed that NP69 cells transfected with pcDNA3-LATS2 showed a 2.66-fold increase in LATS2 protein expression
compared to cells transfected with vector. C, MTT assay was used for analysis of the effect of LATS2 on NP69 cell proliferation. Results represent
the means ± SD (n = 3).*p < 0.05.
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correlated to the patients survival (P = 0.471, Additional
file 2). p-YAP expression was also not correlated with
expression of LATS2 (Spearman’s correlation coefficient
r = 0.146, p = 0.109). Thus, there may be other factors
involved in phosphorylation of YAP in NPC.
There are contradictory reports in the literature
regarding the enhancing and/or inhibitory effect of
LATS2 on cell survival. LATS2-/- embryos exhibit apop-
tosis and an arrest in proliferation, whereas LATS2-/-
mouse embryonic fibroblasts (MEFs) acquire growth
advantages and display a profound defect in contact
inhibition of cell growth [20,21]. In lung cancer cell
lines (A549 and H1299), overexpression of LATS2
induces apoptosis [18], while it rescues apoptosis
induced by nocodazole in the U2OS cell line [19]. Over-
expression of LATS2 in Hela cells can cause G2/M
arrest [16], while in transformed NIH-3T3 cells, excess
LATS2 inhibits G1/S transition [17]. In the present
study, the results showed that siRNA-mediated inhibi-
tion of LATS2 expression in the human NPC cell line
led to inhibition of cell growth, induction of apoptosis
and S-phase increase. Overexpression of LATS2 in the
NP69 cell line stimulated cell growth. This is consistent
with previous studies in LATS2-/- embryos and U2OS
cells, but different from results obtained with lung can-
cer cells and Hela cells. Thus, the effects of LATS2 on
cell proliferation or apoptosis seem to be dependent on
cell type or cell status. The precise mechanism underly-
ing LATS2 regulated cell survival in NPC needs to be
investigated in future studies.
Conclusions
The present work provides the first evidence of the over-
expression of LATS2 in NPC tumor tissues. Overexpres-
sion of LATS2 in NPC tumor tissue is an indicator of
poor prognosis in NPC patients. SiRNA-mediated down-
regulation of LATS2 expression results in the inhibition
of cell growth, induction of apoptosis and S-phase
increase. Overexpression of LATS2 stimulates cell
growth. These results suggest that LATS2 might play a
role in the tumorigenesis of NPC and might be a poten-
tial therapeutic target for NPC treatment.
Additional material
Additional file 1: Specificity evaluation of LATS2 by
immunohistochemistry. A, NPC tumor tissues section were incubated in
LATS2 primary antibody. B, NPC tumor tssues section were incubated
with a non-immunized goat IgG antibody. C, 5-8F cells on the slide were
incubated in LATS2 primary antibody. D, 5-8F cells on the slide were
incubated with a non-immunized goat IgG antibody. E, LATS2 staining of
5-8F cells transfected with control siRNA. F, LATS2 staining of 5-8F cells
transfected with 25 nM LATS2 siRNA1. G, LATS2 staining of 5-8F cells
transfected with 50 nM LATS2 siRNA1. H, LATS2 staining of 5-8F cells
transfected with 75 nM LATS2 siRNA1.
Additional file 2: Expression of p-YAP in NPC tissue and its
association with survival of NPC patients. A, Expression of p-YAP was
determined by immunohistochemistry in 122 NPC tissues. p-YAP was
detected in the cytoplasm and nuclear of the NPC tumor cells and
nasopharyngeal epithelium cells. B, No significant differences in five-year
survival rates were found between low levels of p-YAP expression (n =
73) and high levels of p-YAP expression (n = 49) in NPC patients (P =
0.471). C, No significant differences in five-year survival rates were found
between low levels of p-YAP expression (n = 19) and high levels of p-
YAP expression (n = 12) in NPC patients with early stage disease (stage I
- II, P = 0.472). D, No significant differences in five-year survival rates
were found between low levels of p-YAP expression (n = 54) and high
levels of p-YAP expression (n = 37) in NPC patients with late stage
disease (stage III - IV, P = 0.380).
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